drugset / Trial / NCT03651856

Atomoxetine for Freezing of Gait in Parkinson's Disease

NCT03651856

Phase 3 Completed 10 enrolled Medical University of South Carolina
NaSingle-groupOpen-labelTreatment

Summary

Subjects are being asked to participate in this study to determine the safety and effectiveness of a drug called atomoxetine in the treatment of freezing of gait for Parkinson's Disease patients. Atomoxetine (ATM) is an approved drug currently on the market for the treatment of attention deficit. It works to increase the amount of norepinephrine (a chemical in the brain that helps keep us awake and alert) in our brain. ATM has not been approved by the Food and Drug Administration (FDA) to be used in the treatment of PD, but has been found to be well tolerated in this patient population.

Timeline

Start
2013-01
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 40 mg